[Idursulfase (Elaprase) in the treatment of mucopolisacaridosis II
Catalan Agency for Health Technology Assessment and Research (CAHTA)
Record ID 32010000727
To assess the efficacy, safety and efficiency of idursulfase versus any other treatment alternatives, including placebo, in patients with MPS II.
Authors' recomendations: Idursulfase has demonstrated short term efficacy in patients with non-advanced forms of MPS II when compared to placebo. However, the clinical relevance of these results is unknown. No evidence has been published on the benefits of idursulfase in terms of quality of life.
Project Status: Completed
Year Published: 2010
URL for published report: http://www.gencat.cat/salut/depsan/units/aatrm/pdf/idursulfasa_mucopolisacaridosi_aatrm2010ca.pdf
URL for additional information: http://www.gencat.cat/salut/depsan/units/aatrm/pdf/idursulfasa_recomanacions_aatrm2010ca.pdf
English language abstract: An English language summary is available
Publication Type: Not Assigned
- Iduronate Sulfatase
- Mucopolysaccharidosis II
Organisation Name: Agencia de Qualitat i Avaluacio Sanitries de Catalunya
Contact Address: Antoni Parada, CAHTA, Roc Boronat, 81-95 (2nd floor), 08005 Barcelona, Spain, Tel. +34 935 513 928, Fax: +34 935 517 510
Contact Name: email@example.com / firstname.lastname@example.org
Contact Email: email@example.com / firstname.lastname@example.org
Copyright: Catalan Agency for Health Technology Assessment and Research (CAHTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.